https://peptidebureau.com/lilly-retatrutide-transcend-t2d-2-ozempic-head-to-head.html Peptide Bureauen 2026-10-31T15:08:00+00:00 Lilly Reports Retatrutide Lowered A1C and Weight More Than Ozempic 2 mg in a Phase 3 Head-to-Head. Here Is What the Release Shows and What It Does Not https://peptidebureau.com/australia-peptide-death-finding-victoria-anaphylaxis-advisory.html Peptide Bureauen 2026-10-31T14:15:00+00:00 Victoria Reported 13 Anaphylaxis Cases Associated With Unapproved Peptides, and a Coroner Linked a Death to CJC-1295 and Ipamorelin https://peptidebureau.com/hhs-peptide-enforcement-discretion-policy-published.html Peptide Bureauen 2026-10-31T13:54:00+00:00 HHS Published Its Peptide Compounding Policy: Six Peptides, Ten Conditions, and What the Text Leaves Out